Sparsentan: Patient-reported Outcomes in the Phase 3 DUPLEX Study
Sparsentan in Pediatric Patients With Rare Proteinuric Kidney Disease: Preliminary Findings From the EPPIK Study
Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan
Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)
Sparsentan Improves Glomerular Hemodynamics, Cell Functions and Tissue Repair in a Mouse Model of FSGS
Sparsentan Ameliorates Glomerular Hypercellularity and Inflammatory-gene Networks Induced by IgA1-IgA Immune Complexes in a Mouse Model of IgA Nephropathy
Sparsentan: The First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
Sparsentan Is Superior to Losartan in the gddY Mouse Model 1 of IgA Nephropathy
Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile
Sparsentan Has Direct Effects on the Glomerular Capillary Wall to Attentuate Increased Permeability After Exposure to Nephrotic Syndrome Plasma
American Nephrology Nurses Association (ANNA) Annual Symposium 2024
April 14 - 17, 2024
FL
American Society of Nephrology (ASN) Kidney Week 2024
October 23 - 27, 2024
CA
PROTECT and NefIgArd 2-Year Proteinuria and eGFR Outcomes in Adults with IgA Nephropathy: Matching-Adjusted Indirect Comparison (MAIC)